Semaglutide reduces drinking in adults with alcohol use disorder and obesity

Weekly doses of semaglutide were more effective than placebo in reducing heavy drinking in patients with alcohol use disorder (AUD) and comorbid obesity, a 26‐week trial has found. Semaglutide also resulted in improvement in several metabolic measures, including weight and body mass index (BMI). Study results were published online May 2, 2026 in The Lancet .

Publication Details

Journal
The Brown University Psychopharmacology Update
Published
2026-06-28
DOI
https://doi.org/10.1002/pu.31472
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Semaglutide reduces drinking in adults with alcohol use disorder and obesity

The Brown University Psychopharmacology Update
Diabetes Treatment and Management
article

Semaglutide reduces drinking in adults with alcohol use disorder and obesity

article en

Abstract

Weekly doses of semaglutide were more effective than placebo in reducing heavy drinking in patients with alcohol use disorder (AUD) and comorbid obesity, a 26‐week trial has found. Semaglutide also resulted in improvement in several metabolic measures, including weight and body mass index (BMI). Study results were published online May 2, 2026 in The Lancet .

The Brown University Psychopharmacology UpdateVol. 37(8)
Good health and well-being
Openalex Percentile: Top 8%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.